Ernexa Therapeutics (ERNAW) Notes Payables (2013 - 2025)

Ernexa Therapeutics' (ERNAW) quarterly Notes Payables came in at $2.2 million in Q1 2025, down 54.32% on a QoQ basis from $4.9 million in Q3 2024.

Analysis

Ernexa Therapeutics (ERNAW) Notes Payables (2013 - 2025) Analysis & Trends

Ernexa Therapeutics (ERNAW) has 4 years of Notes Payables data on file, last reported at $2.2 million in Q1 2025.

Quarterly Notes Payables changed N/A year-over-year to $2.2 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $2.2 million (changed N/A YoY) and the FY2013 annual result came in at $631000.0, changed N/A from the prior year.
Notes Payables slipped to $2.2 million in Q1 2025, from $4.9 million in the prior quarter.
In the past five years, Notes Payables ranged from a high of $4.9 million in Q3 2024 to a low of $2.2 million in Q1 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Ernexa Therapeutics	67,312.70	67,312.70	-

Historic Data

Download Data